asxinsights.com is no better than an 'unsigned broker report' if the author cannot publicly identify themselves. Anyone can write just about anything on the internet these days...
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%